Search research articles
Contact Us
Filters
Showing results (221-230 of 276) with videos related to
Page
of 28
Sort By:
The New England Journal of Medicine
|
June 3, 2026
All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia
Gail J Roboz, Amer M Zeidan, Gabriel N Mannis, et al.
Leukemia & Lymphoma
|
July 29, 2021
A 2:1 randomized, open-label, phase II study of selinexor vs. physician's choice in older patients with relapsed or refractory acute myeloid leukemia
Kendra Sweet, Bhavana Bhatnagar, Hartmut Döhner, et al.
Blood Advances
|
June 5, 2023
Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study
Pierre Fenaux, Marco Gobbi, Patricia L Kropf, et al.
Blood
|
May 4, 2022
Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy
Amer M Zeidan, Pierre Fenaux, Marco Gobbi, et al.
Ejhaem
|
July 18, 2022
Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the Connect<sup>®</sup> MDS/AML Disease Registry
Daniel A Pollyea, Tracy I George, Mehrdad Abedi, et al.
Leukemia & Lymphoma
|
July 3, 2018
Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia
Maximilian Stahl, Michelle DeVeaux, Pau Montesinos, et al.
Future Oncology (London, England)
|
March 7, 2025
A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML
Guillermo Garcia-Manero, James McCloskey, Elizabeth A Griffiths, et al.
Blood Advances
|
February 24, 2026
Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy
Andrew H Wei, Panayiotis Panayiotidis, Pau Montesinos, et al.
The New England Journal of Medicine
|
December 28, 2020
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission
Andrew H Wei, Hartmut Döhner, Christopher Pocock, et al.
Cancer Discovery
|
May 12, 2019
Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML
Cihangir Duy, Matt Teater, Francine E Garrett-Bakelman, et al.
Page
of 28
Search research articles
Search
Showing results (221-230 of 276) with videos related to
Sort By:
Page
of 28
The New England Journal of Medicine
|
June 3, 2026
All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia
Gail J Roboz, Amer M Zeidan, Gabriel N Mannis, et al.
Leukemia & Lymphoma
|
July 29, 2021
A 2:1 randomized, open-label, phase II study of selinexor vs. physician's choice in older patients with relapsed or refractory acute myeloid leukemia
Kendra Sweet, Bhavana Bhatnagar, Hartmut Döhner, et al.
Blood Advances
|
June 5, 2023
Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study
Pierre Fenaux, Marco Gobbi, Patricia L Kropf, et al.
Blood
|
May 4, 2022
Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy
Amer M Zeidan, Pierre Fenaux, Marco Gobbi, et al.
Ejhaem
|
July 18, 2022
Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the Connect<sup>®</sup> MDS/AML Disease Registry
Daniel A Pollyea, Tracy I George, Mehrdad Abedi, et al.
Leukemia & Lymphoma
|
July 3, 2018
Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia
Maximilian Stahl, Michelle DeVeaux, Pau Montesinos, et al.
Future Oncology (London, England)
|
March 7, 2025
A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML
Guillermo Garcia-Manero, James McCloskey, Elizabeth A Griffiths, et al.
Blood Advances
|
February 24, 2026
Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy
Andrew H Wei, Panayiotis Panayiotidis, Pau Montesinos, et al.
The New England Journal of Medicine
|
December 28, 2020
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission
Andrew H Wei, Hartmut Döhner, Christopher Pocock, et al.
Cancer Discovery
|
May 12, 2019
Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML
Cihangir Duy, Matt Teater, Francine E Garrett-Bakelman, et al.
Page
of 28